Abstract:e14021 Background: Glioblastoma (GBM) is a highly vascularized tumor and there are few treatment options after disease recurrence. This study assessed the efficacy and safety of anlotinib, a multitarget tyrosine kinase inhibitor, combined with temozolomide in the treatment of these patients. Methods: This is an open-label, single-arm, phase II trial (ChiCTR2000028957). Patients with histologically confirmed GBM with definite progression after surgery followed by radiotherapy and temozolomide chemotherapy were eligible for inclusion. Additional inclusion criteria were 1) 18-70 years old, 2) KPS≥60, 3) disease progression on MRI as defined by Response Assessment in Neuro-Oncology (RANO) criteria at least 12 weeks (wks) after completion of radiotherapy，4) antiangiogenic therapy naïve. All patients received temozolomide (150-200mg/m2, orally, QD, d1-5/4wks) and anlotinib (10mg, orally, QD, d1-14/3wks) until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR, defined as partial and complete responses according to RANO criteria). Safety assessment was done in patients who received at least one dose of study agent. Results: Twenty-one patients (9 males and 12 females) were enrolled between May 2020 and July 2021, and the median age is 55 (range 27-68) years old. Molecular pathological types included MGMT promoter methylated (n = 5), IDH mutation (n = 5), 1p/19q codeletion (n = 8), and TERT promoter mutation (n = 12). Analyses included data collected through December 15, 2021. Tumor response occurred in 17 patients, of which 9 patients had a complete response, and ORR was 81.0% (17/21). There were also 3 patients achieved stable disease and the disease control rate was 95.2% (20/21). Median progression-free survival (PFS) was 13.2 months [95%CI 3.90-22.52], and the PFS at 6 months was 60.0%. The incidence of adverse events of grade 3 was 28.6%, with a higher incidence of elevated AST (25.0%) and ALT (20.0%), hypertension (16.7%), leukopenia (15.4%). No grade 4 or treatment related death occurred in this study through the follow-up. Overall, toxicities are mild and manageable. Conclusions: Anlotinib combined with temozolomide is efficacious and well-tolerated in recurrent GBM patients. Clinical trial information: ChiCTR2000028957.

Pharmacokinetic study on single-dose intravenous temozolomide in glioma patients and health Chinese male volunteers

A phase II study of anlotinib combined with temozolomide in the treatment of patients with recurrent glioblastoma.

Comprehensive analysis of temozolomide treatment for patients with glioma

Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma.

Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies

Phase 2 study of dose-intense temozolomide in recurrent glioblastoma

CTNI-29. A PHASE 2 STUDY TO EVALUATE EFFICACY AND SAFETY OF ACT001 AND TEMOZOLOMIDE COMBINATION TREATMENT IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME

Phase I study of temozolomide in paediatric patients with advanced cancer

Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)

Efficacy of temozolomide in treating recurrent malignant glioma

Phase II study of two-weekly temozolomide in patients with high-grade gliomas

Phase II Study of Protracted Daily Temozolomide for Low-Grade Gliomas in Adults

Comprehensive pharmacogenomics characterization of temozolomide response in gliomas

Temozolomide Dosing Regimens for Glioma Patients

Phase 0 clinical trial of single -dose imatinib mesylate in health Chinese male volunteers

Clinical observation of temozolomide and fotemustine in treating patients with malignant gliomas

Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma

Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas

Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma

Current and future developments in the use of temozolomide for the treatment of brain tumours

Dddr-45. Investigating Temozolomide Resistance In Glioblastoma Using A Clinically Relevant Dosing Regimen